Koola Maju Mathew, Sebastian Joseph
Sheppard Pratt Health System, Baltimore, MD, USA; Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington DC, USA.
Ross University School of Medicine, Portsmouth, Commonwealth of Dominica, West Indies.
HSOA J Psychiatry Depress Anxiety. 2016;2(1). doi: 10.24966/pda-0150/100002. Epub 2016 Feb 23.
Etiologic and pathophysiologic understanding of psychiatric disorders is still in its early stages. The neurobiology of major psychiatric disorders has yet to be fully elucidated. Psychiatric diagnoses are often based on presenting symptoms, lacking reliability and stability. For a variety of reasons, many notable laboratory and clinical observations have not been tested in large trials. Lacking this validation, these potentially valuable practices have not been widely disseminated nor translated into real world practice. Pragmatic practice today requires optimum use of the available resources. This may sometimes require translating novel treatments supported by strong, evidence-based, level II evidence; but still lacking level I evidence into practice and greater utilization of evidence-based approved practices. The purpose of this paper is to highlight some common avoidable pitfalls in practice, and to offer a few psychopharmacological pearls.
对精神障碍的病因学和病理生理学的理解仍处于早期阶段。主要精神障碍的神经生物学尚未完全阐明。精神科诊断通常基于呈现出的症状,缺乏可靠性和稳定性。由于多种原因,许多显著的实验室和临床观察结果尚未在大型试验中得到验证。缺乏这种验证,这些潜在有价值的做法尚未得到广泛传播,也未转化为实际临床实践。当今的务实实践需要优化利用现有资源。这有时可能需要将有强有力的、基于证据的二级证据支持,但仍缺乏一级证据的新型治疗方法转化为实践,并更多地利用基于证据的已批准实践。本文的目的是强调实践中一些常见的可避免的陷阱,并提供一些精神药理学方面的实用建议。